| 19 February 2021
Just as it ratchets up the breath of its offer with a slew of strategic acquisitions, streamer Cinedigm has created two executive roles, SVP revenue and director of programming, to support its the growth of not only its core streaming offers but also and digital business.
In this light, Daniel Schneider has been named senior vice president of revenue and Eric Rowe has been named director of programming. Schneider will manage various streaming and channel business lines throughout their lifecycle by increasing monetisation and using data analytics to make business decisions regarding resource allocation. Previously, he was VP of business development for the digital business at news network Cheddar, leading all distribution across the TV and digital landscape. Schneider scaled the company’s distribution from inception through its sale to comms firm Altice USA.
AMETEK Increases Quarterly Dividend
Share this article
Share this article
BERWYN, Pa., Feb. 11, 2021 /PRNewswire/ AMETEK, Inc. (NYSE: AME) today announced its Board of Directors has approved an 11% increase in its quarterly cash dividend on common stock to $0.20 per share from $0.18 per share. The dividend is payable on March 31, 2021 to shareholders of record as of March 15, 2021. This dividend increase will raise the indicated annual rate to $0.80 per share. AMETEK continues to deliver strong performance through its proven growth model and portfolio of highly differentiated businesses, said David A. Zapico, AMETEK Chairman and Chief Executive Officer. Our ability to generate strong cash flows enables us to both invest in our strategic growth initiatives and deploy meaningful capital on strategic acquisitions, driving long term shareholder value. We remain focused on deploying our free cash flow primarily on strategic acquisitions, while also seeking to reward our shar
AMETEK Announces Fourth Quarter and Full Year Results
News provided by
Share this article
Share this article
BERWYN, Pa., Feb. 4, 2021 /PRNewswire/ AMETEK, Inc. (NYSE: AME) today announced its financial results for the fourth quarter and full year ended December 31, 2020.
AMETEK s fourth quarter 2020 sales were $1.20 billion, an 8% decline compared to the fourth quarter of 2019. Operating income in the quarter was $298.1 million, up slightly versus last year s fourth quarter and operating margins were a record 24.9%, up 210 basis points over the same period last year.
On a GAAP basis, fourth quarter earnings per diluted share were $0.95. Adjusted earnings in the quarter were $1.08 per diluted share, equal to the fourth quarter of 2019. Adjusted earnings adds back non-cash, after-tax, acquisition-related intangible amortization of $0.13 per diluted share. A reconciliation of reported GAAP results to adjusted results is included in the financial tables accompanying this releas
Share this article
Share this article
CHICAGO, Feb. 2, 2021 /PRNewswire/ In-depth analysis and data-driven insights on the impact of COVID-19 included in this Europe cell and gene therapy market report.
The Europe cell and gene therapy market is expected to grow at a CAGR of over 23% during the period 2020−2026.
Key Highlights Offered in the Report:
COVID-19 has negatively impacted the Europe cell and gene therapy market. Most of the raw materials required for the cell and gene therapy are unable to reach the manufacturers. The cell therapy patients and cell donors are not able to access the hospitals, limiting the demand for the cell and gene therapy in Europe.